Linked Life Data

7856282

Source:http://linkedlifedata.com/resource/pubmed/id/7856282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-3-15
pubmed:abstractText
It is known that angiotensin converting enzyme (ACE) inhibitors not only prevent the formation of angiotensin II, but also potentiate the activity of bradykinin. We investigated the effects of the ACE-inhibitor ramipril in two models of cardiac ischemia. In anesthetized dogs with a coronary occlusion of 6-h duration, both ramiprilat and bradykinin significantly reduced infarct-size. This effect was prevented by the co-administration of the bradykinin antagonist HOE 140. In rats with a coronary occlusion of 6-weeks duration, ramipril administration significantly reduced infarct-size and prevented the development of left ventricular hypertrophy. Thus, ramipril showed a cardioprotective activity in models of acute as well as of chronic myocardial ischemia. These effects are probably mediated by the potentiation of bradykinin.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-5860
pubmed:author
pubmed:issnType
Print
pubmed:volume
83 Suppl 4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
63-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
[Reduction of infarct size and remodeling after ramipril].
pubmed:affiliation
Cassella AG, SGE Herz-Kreislauf Therapeutika, Frankfurt/Main.
pubmed:publicationType
Journal Article, English Abstract